Navigation Links
Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
Date:5/3/2012

bringing the total to more than 50 diagnostic sales representatives actively selling in all 50 states in the U.S.

During the first quarter, Sequenom CMM announced the publication of an independent multi-center study on the MaterniT21 LDT, demonstrating that the test can detect fetal trisomy 21, 18 and 13 with high accuracy from a maternal blood sample.  The Company expanded the application of the MaterniT21 LDT to include the detection of trisomies 18 and 13 in addition to trisomy 21, rebranding it under the name MaterniT21™ PLUS.

Conference Call InformationA conference call will take place today, May 3, 2012, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) hosted by Chairman and CEO Harry F. Hixson, Jr., Ph.D., and other members of senior management.  To access the live teleconference call, dial 800-860-2442 in the U.S., 866-605-3852 in Canada (both are toll free), and 412-858-4600 for other international callers.  Please specify to the operator that you would like to join the "Sequenom First Quarter 2012 Earnings Conference Call." If you are unable to listen to the live webcast, a teleconference replay will be available through May 11, 2012.  Interested parties can access the rebroadcast by dialing 877-344-7529 or 412-317-0088 internationally and entering the conference number 10012419.

The conference call webcast is accessible through the "Investors" section of the Sequenom website at http://ir.sequenom.com.  An online replay will be available following the initial broadcast until June 2, 2012. 

About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, a
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sequenom, Inc. Announces Date of Third Quarter 2011 Financial Results and Conference Call
2. Neuland Labs Reports Financial Results For Fiscal Year 2012
3. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
4. GP Strategies Reports Strong First Quarter 2012 EPS of $0.23
5. Cardinal Health Reports Third-Quarter Results
6. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Neurocrine Biosciences Reports First Quarter 2012 Results
9. CVS Caremark Reports Record First Quarter Results
10. National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month
11. Thoratec Reports First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  Vasomedical, Inc. (OTC BB: VASO) ... design, manufacture and sale of medical devices and in the ... Jun Ma , President and CEO of ... MicroCap Conference on Thursday, May 30, 2013 in ... The Company,s presentation is scheduled to begin ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Coherence Tomography (OCT) http://www.reportlinker.com/p01187977/Global-Markets-and-Technologies-for-Optical-Coherence-Tomography-OCT.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ...   BCC,s aim ... synopsis of the current and future characteristics ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... , Beverage Can Stay-Tabs Pose Swallowing Risk ... reports that beverage can stay-tabs pose a potential ingestion risk. ... after safety concerns about pull-tabs. The new study found 19 ... teenagers. Further, the study found that most ingested stay-tabs are ...
... , CHICAGO, Nov. 30 A large ... receive unindicated and unnecessary additional image acquisition resulting in ... today at the annual meeting of the Radiological Society ... of all physicians who work with ionizing radiation to ...
Cached Medicine Technology:Monday, Nov. 30: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago 2Monday, Nov. 30: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago 3Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 2Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 3
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 Global ... organization, and Bodybuilding.com, the largest online retailer of health ... a new reality-based sports show, Warrior Island. “We ... on; YouTube, Facebook & Twitter, with our unique social ... Island maroons these elite fighters on an island in ...
(Date:5/21/2013)... Boston, Mass.By studying the roles two proteins, thrombospondin-1 ... trans-Atlantic research team has identified a five-amino acid ... in mouse models of prostate, breast and lung ... could potentially block metastasis in a variety of ... Randolph Watnick, PhD, at Boston Children,s Hospital, Vivek ...
(Date:5/21/2013)... or the removal of the adenoids and tonsils, is ... often as a treatment for children with obstructive sleep ... child,s attention and executive functioning, behavior, sleep apnea symptoms, ... until now. A study led by Susan Redline, ... and Cardiovascular Medicine and Associate Clinic Director of the ...
(Date:5/21/2013)... Go Classy Tours, the oldest and ... redesigned their website featuring N Resort in Jamaica ... bars and dining. The website, which has always featured ... guest reviews, will now have a broader range of ... on culinary local recipes, flora and fauna, featured pictures ...
(Date:5/21/2013)... 2013 The American Diabetes Association ( ... the United States of America are affected with peripheral ... great risk of developing peripheral neuropathy which unfortunately makes ... ADA further goes on saying that the disease usually ... 2 million new cases are diagnosed every year in ...
Breaking Medicine News(10 mins):Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2
... that points to a new strategy for preventing or possibly ... and tissue damage researchers at the University of ... molecule called Epac (Exchange protein activated by cAMP1), plays a ... The research will be published in the online edition ...
... Specialized Bicycles; Goodby, Silverstein & Partners;, and Google Challenged Participants ... ... ROCK, Ark., April 22 The William J. Clinton,Presidential Center and ... April 26., This year,s festival will host "The Aquaduct: Mobile ...
... of the Cycling Event for the,5th Consecutive Year, ... Store, America,s leading supplier of power wheelchairs and,scooters, raised ... Multiple,Sclerosis Society by participating in the MS150 bike ride., ... a Platinum Sponsor of,the two-day cycling journey from Houston ...
... Abbott (NYSE:,ABT) will present at the Morgan ... 2008. Thomas C. Freyman, executive vice,president, finance and ... company at 7:30 a.m. Central time., A ... accessible through,Abbott,s Investor Relations Web site at ...
... PA, NC, SC, GA and,FL, WEST POINT, ... not-for-profit senior living,organization, announced today that it has ... Cove, a continuing care retirement community (CCRC),in Huntsville, ... May 30., Following the closing of this ...
... in radiology and medical image and information management,solutions, today announced it will ... before the market opens on,Thursday, May 1, 2008., ... -- Thursday, May 1, 2008 ... 7:30 a.m. ...
Cached Medicine News:Health News:Scientists identify novel way to prevent cardiac fibrosis 2Health News:Clinton Center's Earth Day to Feature 'Innovate or Die Contest' Winner 2Health News:The SCOOTER Store and Their Employees Contribute $43,000 in MS150 Bike Ride to Help Texans With Multiple Sclerosis 2Health News:PA-Based ACTS Retirement-Life Communities Announces Agreement to Acquire Carlton Cove in Huntsville, Alabama 2Health News:AMICAS Schedules First Quarter 2008 Earnings Call 2
... is the cycler that revolutionized thermal cycling. ... consistent results, experiment-to-experiment and block-to-block. This rugged ... it's a platform for new features and ... thermal cycler chassis, does not include the ...
... The Gene Cycler unit is an inexpensive personal ... for the PCR process. Lightweight, with a small ... almost anywhere, including the researcher's desk. , The ... researchers who do not have access to a ...
Contains: Card, cabling and instructions to remotely access a RoboCycler® instrument from a PC or Macintosh® computer...
... Ideal for day-to-day temperature ... of 0.1C ,30% reduction ... Peltier or coolant-based cyclers ... temperature ramping ,Options for ...
Medicine Products: